This content was created by Everyday Health Media on behalf of an advertiser.
More Information.
Content on this page was created by the Everyday Health Media team and is funded by an advertiser. The content conforms to Everyday Health Media’s editorial standards for accuracy, objectivity, and balance. The advertiser may select the specialty area but does not edit or approve the content.
Cervical Cancer in Focus
Vaginal Intraepithelial Neoplasia: Risk Factors After Hysterectomy for CIN
A small retrospective study points to advanced age as an independent risk factor for vaginal intraepithelial neoplasia after hysterectomy for cervical intraepithelial neoplasia. Laser vaporization may be the best management approach to reduce risks of further recurrence.
Q&A with Dr. Hunter Holt: The Impact of Being Uninsured or Covered by Medicaid on Advanced Cervical Cancer Diagnosis
How much does being uninsured or covered by Medicaid explain racial and ethnic disparities in the diagnosis of advanced-stage cervical cancer? Dr. Hunter discusses what he and his colleagues learned.
Meeting the Challenge of HPV-Negative Cervical Cancer
Despite upfront therapies being the same in HPV-negative patients, "this represents a completely different type of cancer," says Susana Campos, MD, MPH, of Harvard University and the Dana Farber Cancer institute. The issue lies in distant matastisis, she explains. (1:31)
In Locally Recurrent or Persistent Cervical Cancer, Preoperative Lymph Node Metastasis Predicts Disease Recurrence
Recurrence rates for invasive cervical cancer are high following first-line treatment. The presence of lymph node metastasis predicts recurrence following salvage surgery for locally recurrent or persistent cervical cancer.
HPV-Negative Cervical Cancer Needs More Attention and Research
HPV-negative cervical cancer research and progress has been overshadowed by progress for HPV-positive cervical cancer. Gaps in knowledge regarding biologic characteristics, biomarkers, classification, models, and therapeutic targets need to be addressed.
Less Than Half of Patients with Recurrent or Metastatic Cervical Cancer Receive Second-Line Therapy Following Disease Progressions
Cervical cancer remains an important cause of cancer mortality in the United States, and treatment options remain limited. Less than half of women with r/mCC receive second-line therapy, and second-line therapeutic approaches are inconsistent.